î
îŒ
ãã°ã€ã³
î
BioLine RX Ltd
BLRX2.250USD
-0.080-3.43%
çµå€Â 03/30, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
9.79Mæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
î
詳现æ å ± BioLine RX Ltd äŒæ¥å
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
BioLine RX Ltdã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãBLRX
äŒç€ŸåBioLine RX Ltd
äžå Žæ¥Jan 30, 2007
æé«çµå¶è²¬ä»»è
ãCEOãSerlin (Philip Adam)
åŸæ¥å¡æ°28
蚌åžçš®é¡Depository Receipt
決ç®ææ«Jan 30
æ¬ç€Ÿæåšå°Modi'in Technology Park
éœåžMODIIN
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœIsrael
éµäŸ¿çªå·7177871
é»è©±çªå·97286429100
ãŠã§ããµã€ãhttps://www.biolinerx.com/
äŒæ¥ã³ãŒãBLRX
äžå Žæ¥Jan 30, 2007
æé«çµå¶è²¬ä»»è
ãCEOãSerlin (Philip Adam)
BioLine RX Ltdã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Gal Cohen
Mr. Gal Cohen
Independent Director
Independent Director
--
--
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Raphael (Rafi) Hofstein, Ph.D.
Dr. Raphael (Rafi) Hofstein, Ph.D.
Director
Director
--
--
Ms. Nurit Benjamini
Ms. Nurit Benjamini
External Director
External Director
--
--
Dr. Avraham (Avi) Molcho
Dr. Avraham (Avi) Molcho
External Director
External Director
--
--
Dr. Michael J. Anghel
Dr. Michael J. Anghel
Director
Director
--
--
Mr. Philip Adam (Phil) Serlin
Mr. Philip Adam (Phil) Serlin
Chief Executive Officer
Chief Executive Officer
--
--
Dr. Sandra Panem, Ph.D.
Dr. Sandra Panem, Ph.D.
Director
Director
--
--
Ms. Mali Zeevi
Ms. Mali Zeevi
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Hillit Mannor Shachar
Dr. Hillit Mannor Shachar
Vice President - Business Development
Vice President - Business Development
--
--
詳现ãèŠã
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Gal Cohen
Mr. Gal Cohen
Independent Director
Independent Director
--
--
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Raphael (Rafi) Hofstein, Ph.D.
Dr. Raphael (Rafi) Hofstein, Ph.D.
Director
Director
--
--
Ms. Nurit Benjamini
Ms. Nurit Benjamini
External Director
External Director
--
--
Dr. Avraham (Avi) Molcho
Dr. Avraham (Avi) Molcho
External Director
External Director
--
--
Dr. Michael J. Anghel
Dr. Michael J. Anghel
Director
Director
--
--
åçå èš³
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äºæ¥å¥
å°åå¥
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
æ ªäž»
æŽæ°æå»: Mon, Mar 2
æŽæ°æå»: Mon, Mar 2
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Hong Seng Technology Ltd
3.92%
Citadel Advisors LLC
0.84%
Rhumbline Advisers Ltd. Partnership
0.08%
Intracoastal Capital, L.L.C.
0.07%
Citi Investment Research (US)
0.05%
ä»ã®
95.04%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Hong Seng Technology Ltd
3.92%
Citadel Advisors LLC
0.84%
Rhumbline Advisers Ltd. Partnership
0.08%
Intracoastal Capital, L.L.C.
0.07%
Citi Investment Research (US)
0.05%
ä»ã®
95.04%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Corporation
4.00%
Hedge Fund
0.84%
Investment Advisor
0.13%
Research Firm
0.12%
ä»ã®
94.91%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Mon, Dec 8
æŽæ°æå»: Mon, Dec 8
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2025Q4
62
27.70K
3.92%
--
2025Q3
65
27.70K
4.05%
-38.51K
2025Q2
64
66.21K
2.82%
+56.76K
2025Q1
62
9.46K
4.78%
-168.28K
2024Q4
61
51.31K
6.91%
-11.13K
2024Q3
60
62.45K
12.93%
-43.93K
2024Q2
64
107.06K
9.39%
+72.30K
2024Q1
62
34.99K
9.95%
-145.17K
2023Q4
66
30.65K
11.57%
-4.56K
2023Q3
69
34.99K
12.67%
+3.06K
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
Hong Seng Technology Ltd
170.73K
3.92%
--
--
Mar 16, 2025
Citadel Advisors LLC
10.02K
0.23%
-4.93K
-32.99%
Sep 30, 2025
Rhumbline Advisers Ltd. Partnership
3.07K
0.07%
-1.21K
-28.19%
Sep 30, 2025
Intracoastal Capital, L.L.C.
3.13K
0.07%
+3.13K
--
Mar 16, 2025
UBS Financial Services, Inc.
6.39K
0.15%
+6.39K
--
Sep 30, 2025
Wells Fargo Advisors
1.75K
0.04%
--
--
Sep 30, 2025
Nemes Rush Group, LLC.
250.00
0.01%
--
--
Sep 30, 2025
GWM Advisors LLC
107.00
0%
--
--
Sep 30, 2025
詳现ãèŠã
é¢é£ETF
îæŽæ°æå»: Sat, Dec 6
æŽæ°æå»: Sat, Dec 6
éæå
æ¯ç
ActivePassive International Equity ETF
0%
ActivePassive International Equity ETF
æ¯ç0%
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
ããŒã¿ãªã
æ ªåŒåå²
îæ¥ä»
é
åœèœã¡æ¥
çš®é¡
æ¯ç
Jan 17, 2025
Merger
40â1
Jan 17, 2025
Merger
40â1
Jan 17, 2025
Merger
40â1
Jan 17, 2025
Merger
40â1
æ¥ä»
é
åœèœã¡æ¥
çš®é¡
æ¯ç
Jan 17, 2025
Merger
40â1
Jan 17, 2025
Merger
40â1
Jan 17, 2025
Merger
40â1
Jan 17, 2025
Merger
40â1
